Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336557 · ClinicalTrials.gov registry record
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
A clinical trial, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- 1,230
- Enrollment target
NCT00336557: Completed study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00336557 is a clinical trial that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,230 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00336557 has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- 1,230 participants
- Enrollment target
Study Summary
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Interventions
- PROCEDURE NAbs testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,230 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-07 |
What the finished NCT00336557 record still lists
NCT00336557 is an observational study that tracks outcomes without assigning an intervention. Its 1,230 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which NAbs testing is the first listed.
NCT00336557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00336557 about?
NCT00336557 is a clinical study titled "Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy". An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
What is the current status of trial NCT00336557?
This trial is currently completed. The enrollment target is 1,230 participants. The study started on 2006-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00336557?
The interventions under investigation include: NAbs testing (PROCEDURE).
Who is sponsoring clinical trial NCT00336557?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia